| Dr Laura E Henderson Kelley, MD, MPH | |
|
101 S Fairview Rd, Columbia, MO 65203-7637 | |
| (573) 882-4464 | |
| Not Available |
| Full Name | Dr Laura E Henderson Kelley |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 101 S Fairview Rd, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023073236 | NPI | - | NPPES |
| 001965800 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D0061990 (Maryland) | Secondary |
| 207R00000X | Internal Medicine | D0061990 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.
Research led by Raquel Oliveira, group leader at Instituto Gulbenkian de Ciência, has elucidated how cells are almost blind to chromosome cohesion defects.
Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.
GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.
› Verified 1 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.
Research led by Raquel Oliveira, group leader at Instituto Gulbenkian de Ciência, has elucidated how cells are almost blind to chromosome cohesion defects.
Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.
GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura E Henderson Kelley, MD, MPH 1804 Chapel Ridge Rd, Columbia, MO 65203-4728 Ph: (301) 730-0507 | Dr Laura E Henderson Kelley, MD, MPH 101 S Fairview Rd, Columbia, MO 65203-7637 Ph: (573) 882-4464 |
News Archive
The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.
Research led by Raquel Oliveira, group leader at Instituto Gulbenkian de Ciência, has elucidated how cells are almost blind to chromosome cohesion defects.
Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.
GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.
› Verified 1 days ago
Dr. Rahul Jain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-2296 Fax: 573-884-7743 | |
Gregory Gaskey, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Christos N Papageorgiou, M.D., PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: One Hospital Drive, Columbia, MO 65212 Phone: 573-882-2100 Fax: 573-884-7822 | |
Jack Bragg, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 S Fairview Road, Columbia, MO 65201 Phone: 573-884-7600 Fax: 573-884-8200 | |
Michelle Middleton Woodson, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 Fax: 573-814-6584 | |
Dr. Sameer Bellapravalu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212 Phone: 573-884-6136 Fax: 573-884-1070 | |
Trenton Bickel, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr # Dc043.00, Columbia, MO 65212 Phone: 573-882-7272 |